{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:55Z","timestamp":1791357115010,"version":"4.3.1"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1097\/fpc.0000000000000122","type":"journal-article","created":{"date-parts":[[2015,2,14]],"date-time":"2015-02-14T15:05:49Z","timestamp":1423926349000},"page":"173-185","source":"Crossref","is-referenced-by-count":14,"title":["Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia"],"prefix":"10.1097","volume":"25","author":[{"given":"Dai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyna","family":"Favis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Savitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2008.07.020","article-title":"Schizophrenia, just the facts: what we know in 2008. Part 3: neurobiology.","volume":"106","author":"Keshavan","year":"2008","journal-title":"Schizophr Res"},{"key":"R2-3-20210213","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/ng.940","article-title":"Genome-wide association study identifies five new schizophrenia loci.","volume":"43","year":"2011","journal-title":"Nat Genet"},{"key":"R3-3-20210213","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","article-title":". Common variants conferring risk of schizophrenia.","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"key":"R4-3-20210213","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1093\/hmg\/ddr325","article-title":". Irish Schizophrenia Genomics Consortium. Common variants at VRK2 and TCF4 conferring risk of schizophrenia.","volume":"20","author":"Steinberg","year":"2011","journal-title":"Hum Mol Genet"},{"key":"R5-3-20210213","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci.","volume":"511","year":"2014","journal-title":"Nature"},{"key":"R6-3-20210213","first-page":"285S","article-title":"Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized,double-blind, placebo-controlled study.","volume":"63","author":"Hough","year":"2008","journal-title":"Biol Psych"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","article-title":". Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.","volume":"33","author":"Hough","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":". Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R9-3-20210213","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":". Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.","volume":"69","author":"Meltzer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R10-3-20210213","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":". Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1461145709990988","article-title":". Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.","volume":"13","author":"Kramer","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R13-3-20210213","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":". A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.","volume":"30","author":"Pandina","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R14-3-20210213","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-244X-11-79","article-title":"Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.","volume":"11","author":"Bossie","year":"2011","journal-title":"BMC Psychiatry"},{"key":"R15-3-20210213","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/appi.ajp.158.5.802","article-title":". Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.","volume":"158","author":"Schafer","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R16-3-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2004.11.014","article-title":". Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.","volume":"376","author":"Wu","year":"2005","journal-title":"Neurosci Lett"},{"key":"R17-3-20210213","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1017\/S146114570600719X","article-title":". The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.","volume":"10","author":"Xing","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"R18-3-20210213","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/14622416.9.10.1437","article-title":". Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.","volume":"9","author":"Ikeda","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R19-3-20210213","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","article-title":"D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.","volume":"167","author":"Zhang","year":"2010","journal-title":"Am J Psychiatry"},{"key":"R20-3-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.b.20045","article-title":". Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.","volume":"124B","author":"Szekeres","year":"2004","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R21-3-20210213","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euroneuro.2012.01.006","article-title":"Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes.","volume":"22","author":"Vehof","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"R22-3-20210213","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hup.897","article-title":"Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia Results from treatment responses to risperidone in a naturalistic setting.","volume":"23","author":"Kim","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"R23-3-20210213","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.jcp.0000150226.84371.76","article-title":"Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.","volume":"25","author":"Lane","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R24-3-20210213","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.euroneuro.2004.07.001","article-title":"Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.","volume":"15","author":"Reynolds","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R25-3-20210213","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.npp.1301418","article-title":". Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study.","volume":"33","author":"Xuan","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R26-3-20210213","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.159.9.1593","article-title":"Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.","volume":"159","author":"Lane","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R27-3-20210213","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-9964(98)00032-2","article-title":". Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.","volume":"32","author":"Arranz","year":"1998","journal-title":"Schizophr Res"},{"key":"R28-3-20210213","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-009-1538-z","article-title":"HTR2A A-1438 GT102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.","volume":"205","author":"Chen","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R29-3-20210213","first-page":"109","article-title":". 5-HT2A receptor promoter polymorphism, 1438 GA and negative symptom response to olanzapine in schizophrenia.","volume":"37","author":"Ellingrod","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"R30-3-20210213","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/mp.2008.56","article-title":". Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.","volume":"14","author":"Lavedan","year":"2009","journal-title":"Mol Psychiatry"},{"key":"R31-3-20210213","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/npp.2010.193","article-title":". Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.","volume":"36","author":"McClay","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R32-3-20210213","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FPC.0b013e32835ca260","article-title":". Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.","volume":"23","author":"Clark","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R33-3-20210213","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":". Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.","volume":"25","author":"Gopal","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"R34-3-20210213","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":". A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R35-3-20210213","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":". A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R36-3-20210213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","article-title":". Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.","volume":"16","author":"Tzimos","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"R37-3-20210213","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":". Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"R38-3-20210213","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","article-title":". Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.","volume":"166","author":"Canuso","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R39-3-20210213","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":". A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.","volume":"15","author":"Fleischhacker","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"R40-3-20210213","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/sj.mp.4001983","article-title":". Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia.","volume":"12","author":"Lencz","year":"2007","journal-title":"Mol Psychiatry"},{"key":"R41-3-20210213","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/srep03075","article-title":". GWAS meta analysis identifies TSNARE1 as a novel schizophreniabipolar susceptibility locus.","volume":"3","author":"Sleiman","year":"2013","journal-title":"Sci Rep"},{"key":"R42-3-20210213","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2217\/pgs.14.105","article-title":". SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.","volume":"15","author":"Wang","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R43-3-20210213","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R44-3-20210213","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0920-9964(03)00087-2","article-title":". An excitement subscale of the Positive and Negative Syndrome Scale.","volume":"68","author":"Lindenmayer","year":"2004","journal-title":"Schizophr Res"},{"key":"R45-3-20210213","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.1143767","article-title":". A whole-genome association study of major determinants for host control of HIV-1.","volume":"317","author":"Fellay","year":"2007","journal-title":"Science"},{"key":"R46-3-20210213","first-page":"533","article-title":"Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.","volume":"6","author":"Kim","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"R47-3-20210213","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","article-title":"Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.","volume":"48","author":"Samtani","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R48-3-20210213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.schres.2004.08.020","article-title":". The CC genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia.","volume":"73","author":"Lawford","year":"2005","journal-title":"Schizophr Res"},{"key":"R49-3-20210213","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1503\/jpn.120178","article-title":"COMT neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation.","volume":"38","author":"Ira","year":"2013","journal-title":"J Psychiatry Neurosci"},{"key":"R50-3-20210213","doi-asserted-by":"crossref","first-page":"12768","DOI":"10.1523\/JNEUROSCI.3355-09.2009","article-title":"Understanding the role of DISC1 in psychiatric disease and during normal development.","volume":"29","author":"Brandon","year":"2009","journal-title":"J Neurosci"},{"key":"R51-3-20210213","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.mp.4001586","article-title":". Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia.","volume":"10","author":"Sanders","year":"2005","journal-title":"Mol Psychiatry"},{"key":"R52-3-20210213","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/ng.171","article-title":". Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.","volume":"40","author":"Allen","year":"2008","journal-title":"Nat Genet"},{"key":"R53-3-20210213","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(05)62413-0","article-title":"Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia.","volume":"349","author":"Williams","year":"1997","journal-title":"Lancet"},{"key":"R54-3-20210213","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000129668","article-title":". Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1SLC18A1) on chromosome 8p and schizophrenia.","volume":"57","author":"Lohoff","year":"2008","journal-title":"Neuropsychobiology"},{"key":"R55-3-20210213","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ajmg.b.32079","article-title":"Investigation of allelic heterogeneity of the CCK-A receptor gene in paranoid schizophrenia.","volume":"159B","author":"Zheng","year":"2012","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R56-3-20210213","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1073\/pnas.0903103106","article-title":". Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.","volume":"106","author":"Hindorff","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R58-3-20210213","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(12)62129-1","article-title":"Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"R59-3-20210213","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.mp.4001817","article-title":"Association of the NRG1 gene and schizophrenia: a meta-analysis.","volume":"11","author":"Munafo","year":"2006","journal-title":"Mol Psychiatry"},{"key":"R60-3-20210213","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.yco.0000214341.52249.59","article-title":"An update on the genetics of schizophrenia.","volume":"19","author":"Norton","year":"2006","journal-title":"Curr Opin Psychiatry"},{"key":"R61-3-20210213","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10038-008-0332-9","article-title":". Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a Japanese population.","volume":"53","author":"Shiota","year":"2008","journal-title":"J Hum Genet"},{"key":"R62-3-20210213","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/342734","article-title":". Neuregulin 1 and susceptibility to schizophrenia.","volume":"71","author":"Stefansson","year":"2002","journal-title":"Am J Hum Genet"},{"key":"R63-3-20210213","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/sj.mp.4001991","article-title":". Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene.","volume":"13","author":"Buxbaum","year":"2008","journal-title":"Mol Psychiatry"},{"key":"R64-3-20210213","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn2392","article-title":"Neuregulin 1 in neural development, synaptic plasticity and schizophrenia.","volume":"9","author":"Mei","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"R65-3-20210213","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00213-013-3003-2","article-title":"Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.","volume":"226","author":"Deng","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R66-3-20210213","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.schres.2010.09.001","article-title":"Decreased neuregulin 1 C-terminal fragment in Brodmanns area 6 of patients with schizophrenia.","volume":"124","author":"Barakat","year":"2010","journal-title":"Schizophr Res"},{"key":"R67-3-20210213","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2009.05.015","article-title":". Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine.","volume":"113","author":"Chana","year":"2009","journal-title":"Schizophr Res"},{"key":"R68-3-20210213","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.pnpbp.2011.04.002","article-title":"Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.","volume":"35","author":"Pan","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R69-3-20210213","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1017\/S1461145707008371","article-title":"Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus.","volume":"11","author":"Wang","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"R70-3-20210213","first-page":"620","article-title":". Expressional changes of neuregulin-1 gene mRNA in peripheral blood from schizophrenia patients.","volume":"28","author":"Zhang","year":"2011","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"R71-3-20210213","first-page":"16","article-title":"Neuregulin 1 and age of onset in the major psychoses.","volume":"26","author":"Zhang","year":"2009","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"R72-3-20210213","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1254\/jjp.69.399","article-title":"In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.","volume":"69","author":"Schotte","year":"1995","journal-title":"Jpn J Pharmacol"},{"key":"R73-3-20210213","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","article-title":"AktGSK3 signaling in the action of psychotropic drugs.","volume":"49","author":"Beaulieu","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R74-3-20210213","doi-asserted-by":"crossref","first-page":"26761","DOI":"10.1074\/jbc.272.42.26761","article-title":". A novel juxtamembrane domain isoform of HER4ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester.","volume":"272","author":"Elenius","year":"1997","journal-title":"J Biol Chem"},{"key":"R75-3-20210213","doi-asserted-by":"crossref","first-page":"12165","DOI":"10.1073\/pnas.1206118109","article-title":". Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy.","volume":"109","author":"Law","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"R76-3-20210213","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1073\/pnas.0900355106","article-title":". Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1ErbB signaling in the central nervous system.","volume":"106","author":"Barros","year":"2009","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:22:35Z","timestamp":1620951755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201504000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000122","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}